{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04505358: Phase 2 Interventional Withdrawn Amyotrophic Lateral Sclerosis (ALS)
(2023)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:fipravirimat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:orforglipron [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04083339: Phase 3 Interventional Active, not recruiting Diabetic Cardiomyopathies
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Aldose reductase-IN-1 is an inhibitor of aldose reductase
Status:
Investigational
Source:
NCT03092934: Phase 1/Phase 2 Interventional Completed Neoplasms
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04393753: Phase 2 Interventional Completed Merkel Cell Carcinoma
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
4SC-202 is an epigenetic oncology compound with a unique therapeutic profile, which was developed by biotechnology company: 4SC. 4SC-202 works as a selective inhibitor of LSD1 (lysine-specific demethylase 1) and HDAC (histone deacetylase) 1, 2 and 3. 4SC-202 also strengthens the endogenous immune response to cancer tissue. This compound demonstrated successfully completed Phase I of the clinical study, where it was proved safe and well tolerated in patients with advanced hematologic cancer. In addition, 4SC-202 shows substantial anti-tumor activity in a broad range of cancer cell lines including hepatocellular carcinoma, Urothelial Carcinoma Cell Lines and colorectal cancer.
Status:
Investigational
Source:
INN:bexicaserin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03507790: Phase 2 Interventional Completed Mild to Moderate Alzheimer's Disease
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04066244: Phase 2 Interventional Terminated Amyotrophic Lateral Sclerosis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
BLZ 945, an orally active antagonist of the colony-stimulating factor1
receptor (CSF1R), is being developed by Novartis and Celgene Corporation for the treatment of advanced solid tumors and tumor-induced osteolytic lesions in bone and skeletal-related events. Phase I/II development for solid tumors is underway in the US, Italy, Spain, and Singapore. Preclinical trials were ongoing for tumor-induced osteolysis in Europe and the US. However, no recent reports of development had been identified for this indication.
Status:
Investigational
Source:
NCT02251197: Phase 2 Interventional Completed Stroke
(2001)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Clobenetine is benzomorphan derivative developed by Boehringer-Ingelheim. Clobenetine acts as a sodium channel blocker and displaces radioligand from neurotoxin receptor site 2 of the Na(+) channel in rat brain synaptosomes with IC50 of 49 nM. The IC50 value for the inactivated Na(+) channels was much lower than for Na(+) channels in the resting state. In animal models, clobenetine reduced lesion size in mice and rats when administered 5 min after permanent focal cerebral ischemia at doses that did not impair motor coordination. Clobenetine produced significant analgesic and anti-hyperalgesic effects in the rat model of arthritis, induced by complete Freund's adjuvant. In the early 2000s, the compound was investigated in phase II clinical trial for the treatment of thromboembolic stroke, but no results were reported.
